Skip to main content
Clinical Trials/NCT01619696
NCT01619696
Terminated
Phase 2

Prospective Pilot Study of Multimodal Radiological Evaluation Feasibility During Chemoradiotherapy of Rectal Adenocarcinomas.

University Hospital, Toulouse1 site in 1 country3 target enrollmentMarch 2011

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Rectal Adenocarcinoma
Sponsor
University Hospital, Toulouse
Enrollment
3
Locations
1
Primary Endpoint
acceptation rate of the entire sequence by eligible patients
Status
Terminated
Last Updated
13 years ago

Overview

Brief Summary

The objective of the present project is to validate the feasibility of a multimodal radiological pathway while on chemoradiotherapy, in order to validate potentially predictive factors for chemoradiotherapy sensitivity of rectal adenocarcinomas.

Detailed Description

The objective of the present project is to validate the feasibility of a multimodal radiological pathway while on chemoradiotherapy, in order to validate potentially predictive factors for chemoradiotherapy sensitivity of rectal adenocarcinomas. It is based on a structured clinical and radiological pathway for patients, using diffusion MRI and F misonidazole PET. Validation of these new tools is already needed in clinical practice since future institutional trials will be based on treatment individualisation, using preoperative predicting factors.

Registry
clinicaltrials.gov
Start Date
March 2011
End Date
December 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • locally advanced (≥T3) resectable rectal adenocarcinoma between 2 and 10 cm from the anal verge.

Exclusion Criteria

  • synchonous metastatis
  • previous malignant tumour
  • previous radiotherapy/ chemotherapy
  • performance status WHO\>2
  • contraindication to 5 FU

Outcomes

Primary Outcomes

acceptation rate of the entire sequence by eligible patients

Time Frame: 13 weeks

acceptation rate of the entire sequence by eligible patients

Secondary Outcomes

  • radiological changes while on chimiotherapy, to tumour regression, and prognosis(13 weeks)

Study Sites (1)

Loading locations...

Similar Trials